PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
– Robust Q2 performance with total revenue of $361 million, including $239 million of product revenue – – Full-year 2026 expected total revenue increased to $1.18 to $1.28 billion, with full-year product revenue guidance raised to $850 to $950 million – – Sephience™ (sepiapterin) Q2 2026...
Covered in this story
What has happened since
- PTC Inc. is up 42.3% since this was published, 84 days ago.
- Ptc Therapeutics Inc is down 16.5% since this was published, 84 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on PTC Inc.
- BMO Capital Markets: $192 → $205 by Oct 2027 · Market Perform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PTC yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on PTC Inc. →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.